ABT: Abbott Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT: Abbott Laboratories

ABT 124.51

-1.7%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: HerbVic who wrote (21)	9/10/2003 3:43:51 PM
From: HerbVic	Read Replies (1) of 33

Rising infant-formula sales enhance Martek's bottom line Revenue up sharply from its supplements By TaNoah Morgan Sun Staff Originally published September 10, 2003 With sales of infant formulas enhanced with its supplements increasing, Martek Biosciences Corp. reported sharp gains yesterday in both net income and revenue for its fiscal third quarter. The growth continues the trend of strong sales the company has seen since infant formula makers introduced the formulas with Martek's supplement into the U.S. market last year. <snip> More than 90 percent of the company's third-quarter revenue was generated by sales of its DHA and ARA supplements to Mead Johnson, Wyeth, Abbott Laboratories and Nestle - makers of all of the major brands of infant formulas in the United States and the world, the company said. <snip> sunspot.net

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next